Narmac,

What you propose sounds like a MAJOR change in trial protocol that I would expect Resverlogix and/or members of the Clinical Steering Committee (i.e. Kausik Ray, Kamyar Kalantar-Zadeh) to have disclosed during recent Corporate Updates, MD&A, or scientific presentations. The more likely scenario is that placebo patients are permitted to stay on placebo past the original 104 week limit until trial completion, and apabetalone patients are permitted to stay on apabetalone past the original 104 week limit until trial completion. However, if you are unsatisfied with this response you should contact Resverlogix for clarification. Keep in mind that all patients receive standard of care. Placebo patients aren't being deprived of standard of care treatment.

BearDownAZ